Literature DB >> 27696820

Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease.

Carlos Ramon Nascimento Brito1, Craig S McKay2, Maíra Araújo Azevedo1, Luíza Costa Brandão Santos1, Ana Paula Venuto1, Daniela Ferreira Nunes1, Daniella Alchaar D'Ávila1, Gisele Macedo Rodrigues da Cunha1, Igor Correia Almeida3, Ricardo Tostes Gazzinelli1, Lucia Maria Cunha Galvão1, Egler Chiari1, Carlos A Sanhueza2, M G Finn2, Alexandre Ferreira Marques1.   

Abstract

The α-Gal antigen [Galα(1,3)Galβ(1,4)GlcNAcα] is an immunodominant epitope displayed by infective trypomastigote forms of Trypanosoma cruzi, the causative agent of Chagas disease. A virus-like particle displaying a high density of α-Gal was found to be a superior reagent for the ELISA-based serological diagnosis of Chagas disease and the assessment of treatment effectiveness. A panel of sera from patients chronically infected with T. cruzi, both untreated and benznidazole-treated, was compared with sera from patients with leishmaniasis and from healthy donors. The nanoparticle-α-Gal construct allowed for perfect discrimination between Chagas patients and the others, avoiding false negative and false positive results obtained with current state-of-the-art reagents. As previously reported with purified α-Gal-containing glycosylphosphatidylinositol-anchored mucins, the current study also showed concentrations of anti-α-Gal IgG to decrease substantially in patients receiving treatment with benznidazole, suggesting that the semiquantitative assessment of serum levels of this highly abundant type of antibody can report on disease status in individual patients.

Entities:  

Keywords:  Chagas disease; ELISA; Trypanosoma cruzi; anti-α-Gal antibodies; diagnostics; treatment assessment; α-Gal

Mesh:

Substances:

Year:  2016        PMID: 27696820     DOI: 10.1021/acsinfecdis.6b00114

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  6 in total

1.  Engineering a Virus-like Particle to Display Peptide Insertions Using an Apparent Fitness Landscape.

Authors:  Stephanie A Robinson; Emily C Hartman; Bon C Ikwuagwu; Matthew B Francis; Danielle Tullman-Ercek
Journal:  Biomacromolecules       Date:  2020-09-03       Impact factor: 6.988

Review 2.  Serological Approaches for Trypanosoma cruzi Strain Typing.

Authors:  Virginia Balouz; Leonel Bracco; Alejandro D Ricci; Guadalupe Romer; Fernán Agüero; Carlos A Buscaglia
Journal:  Trends Parasitol       Date:  2021-01-09

3.  A novel antibody surrogate biomarker to monitor parasite persistence in Trypanosoma cruzi-infected patients.

Authors:  Maan Zrein; Elodie Granjon; Lucie Gueyffier; Julie Caillaudeau; Peter Liehl; Hans Pottel; Clareci Silva Cardoso; Claudia Di Lorenzo Oliveira; Lea Campos de Oliveira; Tzong-Hae Lee; Ariela Mota Ferreira; Antonio Luiz P Ribeiro; Michael P Busch; Ester Cerdeira Sabino
Journal:  PLoS Negl Trop Dis       Date:  2018-02-09

4.  Evaluation of the Elecsys Chagas Assay for Detection of Trypanosoma cruzi-Specific Antibodies in a Multicenter Study in Europe and Latin America.

Authors:  Maria Delmans Flores-Chavez; Vittorio Sambri; Volkmar Schottstedt; Fernando Aparicio Higuera-Escalante; Dieter Roessler; Monica Chaves; Tina Laengin; Alfredo Martinez; Bernhard Fleischer
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

5.  Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection.

Authors:  Anna Paula V Moura; Luiza C B Santos; Carlos Ramon Nascimento Brito; Edward Valencia; Caroline Junqueira; Adalberto A P Filho; Mauricio R V Sant'Anna; Nelder F Gontijo; Daniella C Bartholomeu; Ricardo T Fujiwara; Ricardo T Gazzinelli; Craig S McKay; Carlos A Sanhueza; M G Finn; Alexandre Ferreira Marques
Journal:  ACS Cent Sci       Date:  2017-09-13       Impact factor: 14.553

Review 6.  The Glycan Structure of T. cruzi mucins Depends on the Host. Insights on the Chameleonic Galactose.

Authors:  María Eugenia Giorgi; Rosa M de Lederkremer
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.